View in EDS HTML Full Text PDF Full Text

Dramatic response to delayed treatment with tocilizumab in new-onset refractory status epilepticus.

Saved in:
Bibliographic Details
Title: Dramatic response to delayed treatment with tocilizumab in new-onset refractory status epilepticus.
Authors: Pasqualini, Nicholas (AUTHOR), Falcicchio, Giovanni (AUTHOR), Vogrig, Alberto (AUTHOR), Pellicciari, Roberta (AUTHOR), Defazio, Giovanni (AUTHOR), Gelormini, Domenico (AUTHOR), Liviero, Marilena Casartelli (AUTHOR), Gottin, Leonardo (AUTHOR), Bonetti, Bruno (AUTHOR), Zivelonghi, Cecilia (AUTHOR), Ferlisi, Monica (AUTHOR), Zanoni, Tiziano (AUTHOR)
Source: Neurological Sciences. Jul2025, Vol. 46 Issue 7, p3281-3285. 5p.
Subjects: Interleukin-6 receptors, Status epilepticus, Medical sciences, Treatment delay (Medicine), Tocilizumab
Abstract: New-Onset Refractory Status Epilepticus (NORSE) is a severe condition characterized by seizures that are refractory to conventional treatments and in which a clearly recognizable cause cannot be found, posing significant diagnostic and therapeutic challenges. However, recent evidence suggests an underlying immunopathogenic mechanism. We present two clinical cases of NORSE that showed an impressive electroclinical response to tocilizumab, an interleukin-6 receptor antagonist, despite it was administered several weeks after the onset of the symptoms. These findings suggest the role of a suspected aberrant immune response not only in the pathogenesis, but also in the maintenance of this pathological condition, highlighting the importance of considering immunomodulatory interventions in refractory epilepsy cases and raising potential questions regarding the most ideal timing and sequence of therapeutic strategies. In conclusion, tocilizumab may represent a promising therapeutic strategy for NORSE, even if administered late in the course of this pathological condition. Further research is needed to elucidate the possible underlying immunopathogenic mechanisms and to establish the efficacy and safety of immunomodulatory interventions in NORSE. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 185842467
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dramatic response to delayed treatment with tocilizumab in new-onset refractory status epilepticus.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Pasqualini%2C+Nicholas%22">Pasqualini, Nicholas</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Falcicchio%2C+Giovanni%22">Falcicchio, Giovanni</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vogrig%2C+Alberto%22">Vogrig, Alberto</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pellicciari%2C+Roberta%22">Pellicciari, Roberta</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Defazio%2C+Giovanni%22">Defazio, Giovanni</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gelormini%2C+Domenico%22">Gelormini, Domenico</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liviero%2C+Marilena+Casartelli%22">Liviero, Marilena Casartelli</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gottin%2C+Leonardo%22">Gottin, Leonardo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bonetti%2C+Bruno%22">Bonetti, Bruno</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zivelonghi%2C+Cecilia%22">Zivelonghi, Cecilia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ferlisi%2C+Monica%22">Ferlisi, Monica</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zanoni%2C+Tiziano%22">Zanoni, Tiziano</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Jul2025, Vol. 46 Issue 7, p3281-3285. 5p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Interleukin-6+receptors%22">Interleukin-6 receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Status+epilepticus%22">Status epilepticus</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+sciences%22">Medical sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+delay+%28Medicine%29%22">Treatment delay (Medicine)</searchLink><br /><searchLink fieldCode="DE" term="%22Tocilizumab%22">Tocilizumab</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: New-Onset Refractory Status Epilepticus (NORSE) is a severe condition characterized by seizures that are refractory to conventional treatments and in which a clearly recognizable cause cannot be found, posing significant diagnostic and therapeutic challenges. However, recent evidence suggests an underlying immunopathogenic mechanism. We present two clinical cases of NORSE that showed an impressive electroclinical response to tocilizumab, an interleukin-6 receptor antagonist, despite it was administered several weeks after the onset of the symptoms. These findings suggest the role of a suspected aberrant immune response not only in the pathogenesis, but also in the maintenance of this pathological condition, highlighting the importance of considering immunomodulatory interventions in refractory epilepsy cases and raising potential questions regarding the most ideal timing and sequence of therapeutic strategies. In conclusion, tocilizumab may represent a promising therapeutic strategy for NORSE, even if administered late in the course of this pathological condition. Further research is needed to elucidate the possible underlying immunopathogenic mechanisms and to establish the efficacy and safety of immunomodulatory interventions in NORSE. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=185842467
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-025-08108-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 3281
    Subjects:
      – SubjectFull: Interleukin-6 receptors
        Type: general
      – SubjectFull: Status epilepticus
        Type: general
      – SubjectFull: Medical sciences
        Type: general
      – SubjectFull: Treatment delay (Medicine)
        Type: general
      – SubjectFull: Tocilizumab
        Type: general
    Titles:
      – TitleFull: Dramatic response to delayed treatment with tocilizumab in new-onset refractory status epilepticus.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pasqualini, Nicholas
      – PersonEntity:
          Name:
            NameFull: Falcicchio, Giovanni
      – PersonEntity:
          Name:
            NameFull: Vogrig, Alberto
      – PersonEntity:
          Name:
            NameFull: Pellicciari, Roberta
      – PersonEntity:
          Name:
            NameFull: Defazio, Giovanni
      – PersonEntity:
          Name:
            NameFull: Gelormini, Domenico
      – PersonEntity:
          Name:
            NameFull: Liviero, Marilena Casartelli
      – PersonEntity:
          Name:
            NameFull: Gottin, Leonardo
      – PersonEntity:
          Name:
            NameFull: Bonetti, Bruno
      – PersonEntity:
          Name:
            NameFull: Zivelonghi, Cecilia
      – PersonEntity:
          Name:
            NameFull: Ferlisi, Monica
      – PersonEntity:
          Name:
            NameFull: Zanoni, Tiziano
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: Jul2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 46
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1